Research Overview
· Last Reviewed May 2, 2026· PSI Editorial Board· IndependentCan Peptides Improve My Memory?
The honest map across 6 memory scenarios: what's been studied, what's reached human trials, and where validated treatments still rule.
WHAT'S YOUR PRIMARY INTEREST?
Memory Domain
Animal Studies
Human Trials
Alzheimer's disease cognitive symptoms
diagnosed AD
Vascular dementia memory symptoms
post-stroke cognitive decline
Normal age-related memory changes
subjective cognitive decline
Working memory under load
complex task performance
Hippocampal-dependent learning
Morris water maze paradigms
NGF deficit and tau pathology
preclinical Alzheimer's research
Memory consolidation and synaptic plasticity
dendritic spinogenesis substrate
Post-stroke memory recovery
cognitive recovery after stroke
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Memory peptides span international approval for adjuvant Alzheimer's through preclinical-only research compounds. None has US FDA approval for memory enhancement or any memory-specific indication. The validated treatments for Alzheimer's disease are FDA-approved cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonist (memantine), and anti-amyloid antibodies (lecanemab, donanemab). The validated approaches for normal age-related memory changes are sleep optimization, structured exercise, Mediterranean dietary patterns, social engagement, and cognitive activity.
Cerebrolysin has the deepest clinical evidence on this page. The compound is approved in 50+ countries for ischemic stroke recovery, traumatic brain injury, vascular dementia, and adjunctive Alzheimer's disease. Phase 3 trials including Alvarez et al. demonstrated cognitive improvements when added to donepezil. The mechanism is neurotrophic mimicry (BDNF/NGF/GDNF/CNTF). It is NOT US FDA-approved.
Semax is registered in the Russian Medicines Registry for ischemic stroke recovery and cognitive disorders. The mechanism is BDNF and NGF expression upregulation. Russian clinical literature documents memory and cognitive performance improvements in healthy subjects under cognitive load. Western controlled trials in memory indications are absent.
Dihexa is a synthetic angiotensin-IV-derived hexapeptide developed by the Wright laboratory. The mechanism is HGF/c-Met receptor augmentation triggering dendritic spinogenesis. Animal models show dramatic memory enhancement in Morris water maze and aged-rat learning paradigms. Zero published human trials exist.
P21 (acidic-Y17) is a small NGF mimetic peptide developed by the Iqbal laboratory at NYU. The mechanism is selective activation of TrkA without binding p75NTR (avoiding the apoptotic signaling that limits NGF therapy). Animal models in transgenic Alzheimer's mice show reduced tau hyperphosphorylation and preserved memory. Zero published human trials.
The honest framing: peptide research for memory is preliminary outside Cerebrolysin's documented dementia evidence base. The validated FDA-approved Alzheimer's treatments and lifestyle interventions remain the dominant evidence base. For broader cognitive context, see the Peptides for Cognitive Enhancement hub, Peptides for Cognitive Decline, and Peptides for Focus.
Peptides vs FDA-approved Alzheimer's treatments
Where research peptides stand against the validated AD evidence base
The validated treatments for Alzheimer's disease have decades of Phase 3 trial evidence. The honest comparison: peptides at this stage are research-grade biology with limited or no controlled human memory trial evidence in the United States. The FDA-approved AD treatments have established efficacy but modest effect sizes; emerging anti-amyloid antibodies have larger effect sizes with serious safety considerations.
Cholinesterase inhibitors (donepezil/Aricept, rivastigmine/Exelon, galantamine/Razadyne) are first-line for mild-to-moderate Alzheimer's. Multiple Phase 3 trials demonstrate symptomatic improvement on cognitive scales like ADAS-cog and MMSE. Effect sizes are modest. They do not modify disease progression. Side effects include nausea, diarrhea, and bradycardia.
Memantine (Namenda), an NMDA receptor antagonist, is approved for moderate-to-severe Alzheimer's. Phase 3 trials demonstrate symptomatic improvement and reduced functional decline. Often combined with cholinesterase inhibitors. Generally well-tolerated.
Anti-amyloid antibodies represent the major AD treatment advance of recent years. Lecanemab (Leqembi) received FDA accelerated approval in 2023 and traditional approval in 2023 based on the CLARITY-AD Phase 3 trial showing 27% slowing of cognitive decline at 18 months. Donanemab (Kisunla) received FDA approval in 2024 based on the TRAILBLAZER-ALZ 2 Phase 3 trial showing 35% slowing of decline. Both come with serious safety considerations including amyloid-related imaging abnormalities (ARIA) requiring MRI monitoring. They are first-line for early symptomatic AD with confirmed amyloid pathology.
Cerebrolysin sits in the international AD adjuvant evidence base. Alvarez 2011 demonstrated cognitive improvement when added to donepezil. The compound is approved in 50+ countries for adjuvant Alzheimer's and vascular dementia. It is NOT US FDA-approved. Effect size is modest. Comparison against anti-amyloid antibodies has not been adequately powered.
Semax has Russian clinical literature in cognitive performance under load. Western controlled trials in AD specifically are absent. Dihexa and P21 have preclinical-only evidence in transgenic AD models with zero human trials.
PSI's reading: for diagnosed Alzheimer's disease, FDA-approved cholinesterase inhibitors, memantine, and anti-amyloid antibodies are the validated standards. Patients should work with neurology on validated treatment. Cerebrolysin may be discussed as adjunct where international access is available, with Awareness that US approval pathway is not active. Peptide research-grade adjunct discussion may have a role for some patients but should not substitute for validated AD treatment.
Peptides vs lifestyle interventions for normal age-related memory changes
Sleep, exercise, Mediterranean diet, and cognitive activity
Most adults concerned about memory are experiencing normal age-related changes rather than diagnosed dementia. The validated comparison set centers on lifestyle interventions with extensive cohort and trial evidence.
Sleep is the highest-impact intervention for memory consolidation. Memory consolidation occurs during slow-wave sleep and REM sleep. Chronic sleep deprivation impairs hippocampal-dependent memory formation. Sleep duration of 7 to 9 hours nightly correlates with preserved memory performance across the lifespan. Treatment of sleep apnea via CPAP often produces measurable memory improvement within weeks.
Aerobic exercise of 150 minutes weekly improves memory performance and reduces hippocampal atrophy in cohort studies. Resistance training adds independent cognitive benefits. The PREDIMED-Plus trial demonstrated cognitive benefits of Mediterranean dietary patterns combined with exercise in older adults at risk for cognitive decline. The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) has emerging trial evidence for reduced cognitive decline rates.
Cognitive engagement through social interaction, lifelong learning, and complex cognitive activity correlates with reduced dementia risk in cohort studies. Computer-based cognitive training programs show modest evidence for specific cognitive domains; transfer to real-world memory function is debated.
Treatment of underlying conditions often produces larger memory effects than direct enhancement. Hypothyroidism, depression, vitamin B12 deficiency, low vitamin D, and untreated obstructive sleep apnea all produce reversible memory complaints that resolve with appropriate treatment.
PSI's reading: for normal age-related memory changes, sleep optimization, structured exercise, Mediterranean dietary patterns, social engagement, cognitive activity, and treatment of underlying conditions are the dominant evidence base. These have effect sizes peptide research has not yet matched. Anyone framing peptides as substitutes for lifestyle interventions or treatment of underlying conditions is reading further into the data than the data supports.
Cerebrolysin vs anti-amyloid antibodies for early Alzheimer's
International peptide evidence vs US-approved emerging therapies
The Alzheimer's treatment landscape changed substantially with FDA approval of lecanemab (Leqembi) in 2023 and donanemab (Kisunla) in 2024. Both are anti-amyloid monoclonal antibodies that clear amyloid plaques and demonstrably slow cognitive decline.
Lecanemab Phase 3 CLARITY-AD trial: 27% slowing of cognitive decline (CDR-SB) at 18 months in early symptomatic AD with confirmed amyloid pathology. Donanemab Phase 3 TRAILBLAZER-ALZ 2 trial: 35% slowing of cognitive decline (iADRS) at 76 weeks. Both produce measurable amyloid plaque reduction on PET imaging. Both come with serious safety considerations including amyloid-related imaging abnormalities (ARIA-E for edema, ARIA-H for hemorrhage) requiring frequent MRI monitoring.
Cerebrolysin sits in a different evidence position. Alvarez 2011 Phase 3 in moderate-to-moderately-severe AD demonstrated cognitive improvement on ADAS-cog when added to donepezil. The compound is approved in 50+ countries. The mechanism is neurotrophic mimicry rather than amyloid plaque clearance. Direct head-to-head trials against anti-amyloid antibodies have not been completed.
PSI's reading: for early symptomatic Alzheimer's with confirmed amyloid pathology, anti-amyloid antibodies (lecanemab, donanemab) are the new validated US standard with the largest effect sizes available. They require careful patient selection and MRI monitoring. Cerebrolysin may have an adjunct role in some international protocols, particularly in moderate-to-moderately-severe disease where antibodies are not first-line. The two treatment categories address different aspects of Alzheimer's pathology and could potentially complement each other in research contexts. Patients should work with neurology on validated treatment selection.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 most-discussed peptides for memory, Cerebrolysin has the deepest clinical evidence (international approval for adjuvant Alzheimer's and vascular dementia). Semax has Russian clinical use. Dihexa and P21 sit at preclinical-only evidence depth with strong mechanism rationales. Here is what each one's trials and animal studies actually show.
Cerebrolysin
Approved in 50+ countries for vascular dementia and adjunctive Alzheimer's. Phase 3 trials demonstrate cognitive improvement when added to cholinesterase inhibitor therapy. Not US-approved.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Domain | Animal Studies | Human Trials |
|---|---|---|
Adjuvant Alzheimer's disease moderate-to-moderately-severe AD | 12 Reduced amyloid pathology and preserved cognitive performance in transgenic Alzheimer's animal models. | 6 Phase 3 trials demonstrated cognitive improvements when added to cholinesterase inhibitor therapy. |
Vascular dementia memory symptoms post-stroke cognitive decline | 8 Improved cognitive performance and reduced white-matter pathology in vascular dementia animal models. | 5 Multiple controlled trials support approval in vascular dementia indications. |
Post-stroke cognitive recovery early post-stroke window | 18 Reduced infarct size and improved cognitive recovery across animal stroke models. | 8 CARS and other Phase 3 RCTs reported cognitive recovery improvements. |
Idiopathic age-related memory complaints no documented dementia | 4 Limited animal data outside dementia models. | 1 No published controlled trials for idiopathic memory complaints specifically. |
Semax
Russian Medicines Registry approved for cognitive disorders. Russian clinical literature on memory and cognitive performance under load. Limited Western validation.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Memory and cognitive performance healthy subjects under load | 10 Improved memory performance in rodent models including under sleep deprivation. | 3 Russian clinical exploratory studies in cognitive performance under load. Western controlled trials absent. |
Ischemic stroke cognitive recovery post-stroke memory component | 14 Improved neurological recovery and BDNF upregulation across animal stroke models. | 4 Russian Phase 3 trials support stroke recovery indication. |
Age-related memory changes subjective cognitive decline | 4 Limited animal data in aged-animal memory paradigms. | 0 No published controlled trials in age-related memory complaints. |
Dihexa
Strongest preclinical memory enhancement signal through HGF/c-Met receptor augmentation and dendritic spinogenesis. Zero published human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Hippocampal-dependent learning Morris water maze | 8 Improved spatial learning and memory in Morris water maze paradigms in healthy and aged rats. | 0 Zero published interventional trials. |
Scopolamine-induced cognitive deficit memory impairment model | 6 Reversed scopolamine-induced learning impairment with effect sizes substantially larger than donepezil. | 0 Zero published trials. |
Age-related memory decline aged-rodent paradigms | 6 Improved memory performance in aged rats versus age-matched controls in radial arm maze and water maze paradigms. | 0 Zero published trials. |
Dendritic spine density structural plasticity | 4 Increased hippocampal dendritic spine density and synaptic markers after subchronic Dihexa administration. | 0 Zero human evidence. |
P21 (acidic-Y17)
Selective TrkA NGF mimetic from Iqbal laboratory. Reduces tau hyperphosphorylation in transgenic AD mouse models. Zero published human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Tau pathology and Alzheimer's preclinical transgenic mouse models | 8 Reduced tau hyperphosphorylation and preserved synaptic markers in 3xTg-AD and Tg2576 mice. | 0 Zero published trials. |
Memory preservation in AD models spatial learning paradigms | 6 Protected memory performance versus untreated transgenic AD controls in spatial learning tasks. | 0 Zero published trials. |
Cholinergic neuron protection NGF mimetic mechanism | 4 Preserved cholinergic neuron markers and TrkA signaling in animal models. | 0 Zero human evidence. |
What's Marketed vs What's Studied
6 common claims, corrected.
“Peptides reverse Alzheimer's disease.”
No peptide reverses Alzheimer's. The validated AD treatments are cholinesterase inhibitors, memantine, and anti-amyloid antibodies; even these slow decline rather than reverse the disease. Peptide research is exploratory at this stage.
“Cerebrolysin is FDA-approved for memory.”
Cerebrolysin is approved in 50+ countries for adjuvant Alzheimer's, vascular dementia, post-stroke recovery, and TBI. It is NOT US FDA-approved for any indication.
“Dihexa works the same way in humans as in animals.”
Dihexa shows striking memory enhancement in animal models including aged-rat learning paradigms. Zero published human trials exist as of 2026. Animal-model effect sizes do not always translate proportionally to human outcomes.
“P21 is a validated Alzheimer's treatment.”
P21 is a preclinical research peptide developed by the Iqbal laboratory. The selective TrkA mechanism is mechanistically interesting and animal studies in transgenic AD models are promising. Zero published human trials exist.
“Peptides are safer than anti-amyloid antibodies.”
Anti-amyloid antibodies have well-characterized safety profiles from Phase 3 trials including ARIA imaging abnormalities. Long-term safety data for memory peptide use specifically is unknown for the preclinical-only compounds and limited for international compounds. The honest comparison is unequal — antibody risks are characterized; peptide long-term risks are partially uncharacterized.
“I can substitute peptides for my Alzheimer's medication.”
Substituting peptides for validated AD treatment without neurology guidance risks faster cognitive decline. Patients with diagnosed AD should work with neurology on validated treatment.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get a comprehensive memory workup before peptide consideration.
Detailed history, mental status examination, validated cognitive assessment (MoCA, MMSE), TSH, B12, vitamin D, depression and anxiety screening, sleep evaluation, medication review. For persistent memory loss affecting daily function, neurological evaluation including potential neuroimaging.
Exhaust validated FDA-approved treatments first where applicable.
For diagnosed Alzheimer's, cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA antagonist (memantine), and anti-amyloid antibodies (lecanemab, donanemab for early symptomatic AD with confirmed amyloid) carry decades of Phase 3 trial evidence. Beginning with research peptides instead is not appropriate.
Optimize validated lifestyle interventions.
Sleep duration of 7 to 9 hours, aerobic exercise of 150 minutes weekly, Mediterranean dietary patterns, social engagement, cognitive activity, and treatment of cardiovascular risk factors. These have effect sizes peptide research has not yet matched. Optimize before peptide exploration.
Work with a specialist who knows both validated treatments and peptide research.
Avoid clinics whose primary business is selling peptides. A qualified neurologist, geriatrician, or integrative medicine physician with neurology familiarity can frame peptides accurately as research-grade adjuncts and identify when validated escalation is needed.
Compounded peptides require physician prescription and licensed pharmacy.
503A pharmacies prepare patient-specific compounds; 503B outsourcing facilities prepare office-use stock. Both require active state licensure. Demand third-party HPLC purity testing and certificates of analysis.
Track objective cognitive markers, not just subjective sense of memory.
MoCA, MMSE, CDR-SB, computerized cognitive batteries (CANTAB, Cogstate) provide objective assessment. Subjective sense of memory improvement without objective marker improvement is not evidence of effect. Compare peptide adjunct effects against validated treatment using the same objective measures.
The regulatory landscape for memory peptides is dynamic. Cerebrolysin remains approved in 50+ countries with no active US approval pathway. Lecanemab (FDA-approved 2023) and donanemab (FDA-approved 2024) have substantially shifted the Alzheimer's treatment landscape. Anti-amyloid antibody adoption requires patient selection (early symptomatic AD with confirmed amyloid pathology) and ARIA monitoring infrastructure that limits widespread use. The Outsourcing Facilities Association is actively litigating FDA compounding decisions in the Northern District of Texas, which could shift availability of compounded peptide versions. Semax and Selank remain Russian-registered without Western pathway. Dihexa and P21 remain preclinical with no active sponsor-led human trial programs. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any memory peptides FDA-approved in the United States?
No. As of 2026, no peptide on this page is FDA-approved in the United States for any memory indication including Alzheimer's disease, vascular dementia, age-related memory changes, or memory enhancement. The validated FDA-approved treatments for Alzheimer's are cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonist (memantine), and anti-amyloid antibodies (lecanemab, donanemab). For normal age-related memory changes, lifestyle interventions and treatment of underlying conditions are the validated approaches.
Can Cerebrolysin help with my Alzheimer's symptoms?
Cerebrolysin has Phase 3 trial evidence as adjunct to cholinesterase inhibitor therapy in moderate-to-moderately-severe Alzheimer's. The Alvarez 2011 trial demonstrated cognitive improvement on ADAS-cog when added to donepezil. The compound is approved in 50+ countries for adjunctive AD use and vascular dementia. It is NOT US FDA-approved. US patients seeking Cerebrolysin typically import for personal use. PSI's reading: Cerebrolysin may have an adjunct role in some international AD protocols. Patients with diagnosed AD should work with neurology on validated treatment first, including consideration of anti-amyloid antibodies for early symptomatic disease.
How does Cerebrolysin compare to lecanemab or donanemab?
Different mechanisms and evidence bases. Lecanemab and donanemab are anti-amyloid monoclonal antibodies that clear amyloid plaques and demonstrably slow cognitive decline (27% with lecanemab, 35% with donanemab in Phase 3 trials). Both come with serious safety considerations including ARIA imaging abnormalities requiring MRI monitoring. They are first-line for early symptomatic AD with confirmed amyloid pathology. Cerebrolysin is a neurotrophic mimetic with adjuvant cognitive benefit when added to cholinesterase inhibitors. The two address different aspects of AD pathology. Direct head-to-head trials have not been completed.
Is Dihexa actually as effective as the animal studies suggest?
Dihexa shows striking memory and cognitive enhancement in animal models. Wright laboratory paradigms report effect sizes substantially larger than donepezil in scopolamine-induced cognitive deficit. Aged-rat Morris water maze tasks show similar effect direction. The HGF/c-Met receptor augmentation and dendritic spinogenesis mechanism is well-characterized. As of 2026, zero published controlled human trials of synthetic Dihexa exist. The translation from animal-model magnitude to validated human memory enhancement is the missing evidence layer. Animal-model effect sizes do not always translate proportionally to human outcomes.
What about P21 for Alzheimer's prevention?
P21 is a research peptide developed by Khalid Iqbal at NYU. The mechanism is selective TrkA NGF mimetic without p75NTR binding. Animal studies in transgenic Alzheimer's mouse models (3xTg-AD, Tg2576) show reduced tau hyperphosphorylation, preserved synaptic markers, and protection of memory performance. The selective TrkA mechanism addresses the apoptotic side effect that limited earlier full-length NGF protein therapy. As of 2026, zero published controlled human trials exist. P21 is research-only with no FDA approval. Anyone framing P21 as a validated Alzheimer's prevention strategy is reading further into the data than the data supports.
Can peptides replace my cholinesterase inhibitor or memantine?
No peptide on this page has FDA approval for Alzheimer's or has equivalent Phase 3 trial evidence to validated cholinesterase inhibitors and memantine. Substituting peptides for prescribed AD medication risks faster cognitive decline. Patients with diagnosed Alzheimer's should work with neurology on validated treatment. Peptide adjunct discussion may have a research-grade role for patients seeking complementary approaches, but should layer alongside validated treatment under physician supervision, not replace it.
What lifestyle changes have stronger evidence than memory peptides?
Several lifestyle changes have stronger evidence than any peptide on this page for normal age-related memory changes. Sleep duration of 7 to 9 hours nightly supports memory consolidation through slow-wave sleep and REM sleep. Aerobic exercise of 150 minutes weekly improves memory and reduces hippocampal atrophy. Mediterranean dietary patterns (PREDIMED-Plus, MIND diet) have trial evidence for reduced cognitive decline. Social engagement and lifelong learning correlate with reduced dementia risk. Treatment of underlying obstructive sleep apnea, hypothyroidism, depression, vitamin B12 deficiency, and other conditions often resolves memory complaints without peptide exploration.
Should I work with a neurologist if I'm worried about memory loss?
Yes. Persistent memory complaints, especially those affecting daily function, warrant neurological evaluation. Workup typically includes detailed history, mental status examination, validated cognitive assessment (MoCA, MMSE), neuroimaging where indicated, and ruling out reversible causes (thyroid, B12, depression, sleep apnea, medication side effects). For early symptomatic Alzheimer's with confirmed amyloid pathology, anti-amyloid antibody therapy (lecanemab, donanemab) may be appropriate. Validated workup should precede any peptide consideration.
How long does it take memory peptides to show effects?
Cerebrolysin clinical protocols use 10 to 30 day intravenous or intramuscular cycles with measurement at 90 days; cognitive endpoints in trials measured at 28 weeks. Russian Semax protocols typically use 14 to 21 day intranasal courses. Animal Dihexa and P21 protocols measure at 4 to 12 weeks. For comparison, validated treatments have well-characterized timelines. Cholinesterase inhibitors produce measurable cognitive improvement within weeks; effect plateaus at months. Anti-amyloid antibodies produce amyloid clearance over months with cognitive endpoints measured at 18 to 76 weeks. Lifestyle interventions (sleep, exercise) can produce measurable memory improvement within weeks to months.
Are these peptides safer than FDA-approved Alzheimer's drugs?
Long-term safety profiles vary. Cerebrolysin has decades of international clinical safety data; injection-site reactions, mild headache, and rare hypersensitivity are documented. Semax has decades of Russian clinical use. Dihexa and P21 lack human safety data; profiles are inferred from animal toxicology only. FDA-approved AD treatments have well-characterized side-effect profiles including cholinesterase inhibitor GI effects, memantine generally well-tolerated, and anti-amyloid antibody ARIA imaging abnormalities requiring monitoring. The honest comparison: peptide long-term safety is partially or entirely uncharacterized. AD drug long-term safety is well-characterized but includes documented risks.
Can I take Cerebrolysin in addition to my AD medications?
Cerebrolysin is studied specifically as adjunct to cholinesterase inhibitor therapy. The Alvarez 2011 Phase 3 trial used Cerebrolysin plus donepezil versus donepezil alone. Drug-drug interactions appear limited. The compound is administered intravenously or intramuscularly in cycles, separate from oral AD medications. US patients seeking Cerebrolysin import for personal use; specialist neurology guidance is appropriate for adjunct use coordination. Anyone considering combination protocols should discuss specifics with neurology familiar with peptide research.
What about peptides for memory in younger adults?
Memory complaints in younger adults are usually attributable to sleep deprivation, anxiety or depression, attention disorders, medication side effects, or substance use. Workup of these is appropriate first-line. Validated approaches include sleep optimization, treatment of underlying anxiety or depression, evaluation for ADHD if attention deficits are prominent, and lifestyle interventions. Peptide exploration for younger-adult memory complaints is even more preliminary than for age-related changes. Russian Semax literature in cognitive performance under load is the closest research signal. PSI's reading: address validated causes first.
Are these peptides legal in the United States?
Regulatory status varies. None of the peptides on this page is FDA-approved in the United States for any memory indication. Cerebrolysin requires personal import for US use. Semax is research-only with availability through some compounding pharmacies and research-chemical sources. Dihexa and P21 are research-only with limited compounded availability. None is WADA-prohibited. Regulatory status is dynamic.
Can peptides prevent Alzheimer's disease?
No peptide on this page has been validated as Alzheimer's prevention therapy. The validated approaches for cognitive aging include sleep optimization, structured exercise, Mediterranean dietary patterns, social engagement, cognitive activity, treatment of cardiovascular risk factors, and treatment of hearing loss. The FINGER and similar multidomain prevention trials have evidence for reducing cognitive decline rates in at-risk populations. Peptide research for prevention is preliminary. Anyone framing peptides as validated AD prevention is reading further into the data than the data supports.
What questions should I ask a doctor about peptides for memory?
Ask: (1) Have we ruled out reversible causes of memory complaints (thyroid, B12, depression, sleep apnea, medication side effects)? (2) For diagnosed dementia, what FDA-approved treatments (cholinesterase inhibitors, memantine, anti-amyloid antibodies if appropriate) have I tried first? (3) What evidence level supports the peptide being considered for my specific situation? (4) What are the long-term safety considerations for the specific compound? (5) Are the compounded formulations being prescribed from a state-licensed compounding pharmacy with third-party analytical testing? (6) How will we measure whether the peptide is working using objective cognitive assessment tools (MoCA, computerized cognitive batteries)?
Is there validated cognitive assessment I should track?
Yes. Validated cognitive assessment tools include the Montreal Cognitive Assessment (MoCA, brief office assessment), Mini Mental State Examination (MMSE), Clinical Dementia Rating Sum of Boxes (CDR-SB, primary endpoint in many AD trials), and computerized cognitive batteries (CANTAB, Cogstate). Subjective sense of memory improvement without objective marker improvement is not evidence of effect. For research-grade peptide adjunct exploration, baseline and follow-up assessment using consistent tools allows objective evaluation of whether intervention produces measurable benefit.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.